Date Annoucement
12/12/2016 CxBladder update
29/11/2016 Cellmid Receives 831K R&D Tax Credit
21/11/2016 AGM Presentation by CEO
21/11/2016 Results of Annual General Meeting
17/11/2016 Appendix 3Y – Change of Director’s Interest Notice
09/11/2016 Cleansing Statement – Notice under section 708A(5)(e) of the Corporations Act
03/11/2016 Usa Launch of Évolis®
01/11/2016 Appendix 3Y- Change of Director’s Interest Notice
01/11/2016 ASX Market Release – Reinstatement
01/11/2016 Cellmid Capital Raising
01/11/2016 Notes to Appendix 4C
28/10/2016 Notes to the Appendix 3B
26/10/2016 Trading Halt
25/10/2016 Exercise of options (CDYO)
21/10/2016 Appendix 3B – New issue announcement
19/10/2016 Notice of Annual General Meeting
18/10/2016 Change of Directors Interest Notice – Bruce Gordon
18/10/2016 Change of Directors Interest Notice – David King
18/10/2016 Change of Directors Interest Notice – Edward Fintan Walton
18/10/2016 Change of Directors Interest Notice – Maria Halasz
10/10/2016 Cellmid Records Highest Ever Quarterly Sales For Evolis®
05/10/2016 Cellmid’s Midkine Antibodies Show Anti-tumor Activity Against Brain Cancer
30/09/2016 2016 Annual Report
28/09/2016 Quotation of Listed Options
23/09/2016 Expiry of Listed Options (CDYO)
22/09/2016 European Midkine Patent for Surgical Adhesion Allowed
19/09/2016 Change of Directors Interest Notice – Maria Halasz
13/09/2016 Date of Annual General Meeting
31/08/2016 Appendix 4E and Preliminary Final Report
31/08/2016 Appendix 4G – Corporate Governance Statement
09/08/2016 New publication for Cellmid’s Midkine antibody
03/08/2016 Cellmid Investor Presentation
29/07/2016 Transcript of Cellmid Investor Briefing Call
26/07/2016 Appendix 4C – quarterly
22/07/2016 Ikon Legal Action
21/07/2016 Cellmid Investor Briefing
20/07/2016 USA Distribution Partnership for Cellmid’s évolis®
29/06/2016 Midkine interviews with Pharmatelevision published
24/06/2016 MK antibody publication and patent in bone healing
20/06/2016 Change of Directors Interest Notice – Maria Halasz
14/06/2016 évolis Professional Launch
26/05/2016 Record monthly sales for Advangen Japan
11/05/2016 4th MK Symposium Results
09/05/2016 Significant scientific appointment for cellmid advisory board chair
21/04/2016 Appendix 4C – quarterly
08/04/2016 Midkine Strategy Update
04/04/2016 Fourth Midkine Symposium to be held in Budapest
26/02/2016 Cellmid to Refinance RnD Loan
26/02/2016 Transcript of Cellmid Investor Briefing
25/02/2016 Appendix 4D and Half Year Accounts
23/02/2016 Cellmid Investor Briefing
04/02/2016 Appointment of Elizabeth Masamune
27/01/2016 Appendix 4C – quarterly

 

 

Shop évolis®